Mirum Pharmaceuticals, Inc.
MIRM Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$83.27
KIRA · Stoqly’s AI analyst, in plain words
- Mirum Pharmaceuticals, Inc. had $521M of revenue in fiscal 2025, up 54.7% on the year before.
- Its operating margin was −4.2%, up 21.8 pts: of every 100 in sales, about −4 is left after running the business.
- Mirum Pharmaceuticals, Inc. lost $23.4M in fiscal 2025.
- Free cash flow was $54.9M in fiscal 2025, 10.5% of revenue.
Market cap
$5.3B
P/E
—
Revenue
$521M
Net income
−$23.4M
Free cash flow
$54.9M
Operating margin
−4.2%
Mirum Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+54.7%
Yes. Sales grew 54.7% last year.
Does it make a profit?
−4.5%
No. It lost money last year.
Does profit turn into cash?
10.5%
Yes. 10.5% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mirum Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Mirum Pharmaceuticals, Inc.
- CIK
- 0001759425
Mirum Pharmaceuticals, Inc. · MIRM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $19.1M | $77.1M | $186M | $337M | $521M |
| Revenue growth | — | 302.7% | 141.8% | 80.8% | 54.7% |
| Operating margin | −906.1% | −170.3% | −58.6% | −26.0% | −4.2% |
| Net income | −$84.0M | −$136M | −$163M | −$87.9M | −$23.4M |
| Net margin | −438.9% | −176.0% | −87.7% | −26.1% | −4.5% |
| Diluted EPS | −$2.77 | −$4.02 | −$4.00 | −$1.85 | −$0.47 |
| Cash | |||||
| Cash from operations | −$133M | −$120M | −$70.9M | $10.3M | $55.8M |
| Capital expenditure | $0.0M | $0.3M | $0.1M | $1.0M | $1.0M |
| Free cash flow | −$133M | −$120M | −$71.1M | $9.3M | $54.9M |
| FCF margin | −693.8% | −156.3% | −38.1% | 2.8% | 10.5% |
| Share count change | 20.1% | 12.1% | 20.3% | 16.2% | 5.6% |
| Debt and strength | |||||
| Cash and short-term investments | $157M | $152M | $286M | $280M | $383M |
| Shareholders' equity | $120M | $142M | $249M | $226M | $315M |
| Current ratio | 3.9x | 2.9x | 4.5x | 3.1x | 2.7x |
| Interest coverage | — | −8.2x | −7.2x | −6.1x | −1.5x |
| Returns and quality | |||||
| Return on equity | −57.5% | −103.5% | −83.7% | −37.1% | −8.6% |
| Return on tangible equity | −82.8% | −163.3% | — | — | −43.5% |
| Piotroski F-score | 2 | 2 | 4 | 4 | 4 |
| Altman Z'' | −3.3 | −3.1 | −0.2 | −0.9 | 0.5 |
Insiders bought, 12 months
$9.0M
1 insider
Insiders sold, 12 months
$42.2M
7 insiders
Of sales under plans
61%
$25.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mirum Pharmaceuticals, Inc. · MIRM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $83.27 a share, the company is worth $5.3B.
Source: SEC EDGAR XBRL filings (CIK 0001759425). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.